Stand Up To Cancer (SU2C), joined by the Lustgarten Foundation for Pancreatic Cancer Research, LUNGevity, and the American Lung Association, announced today four teams of top researchers who will carry out an attack on cancers of the lung and pancreas using a radical new approach of “interception” of cancers at very early stages, when they can be more successfully treated.

The Mass General Cancer Center's Dr. David Ryan and Dr. Lecia Sequist were named leaders for two of the four teams. Dr. Ryan will be leading the team for Developing Novel Approaches to Treat and Evaluate Early Pancreatic Cancer while Dr. Sequist will be spearheading the team for Blood-based Early Interception of Lung Cancer. For more information, you can find the press release here.